Literature DB >> 12958147

Role of interleukin-6 for LV remodeling and survival after experimental myocardial infarction.

Martin Fuchs1, Andres Hilfiker, Karol Kaminski, Denise Hilfiker-Kleiner, Zeynep Guener, Gunnar Klein, Edith Podewski, Bernhard Schieffer, Stefan Rose-John, Helmut Drexler.   

Abstract

Circulating levels of interleukin (IL)-6 are elevated after myocardial infarction (MI) and associated with increased morbidity and mortality. Its myocardial expression post-MI suggests a pathophysiological role in this condition. To explore the role of endogenous IL-6, we analyzed MI size, left ventricular (LV) remodeling, and mortality after permanent coronary ligation in IL-6 knockout mice (IL-6-/-) and wild-type controls (WT). Six weeks after MI, IL-6-/- and WT had similar mortality rates, MI sizes, LV remodeling, and LV dysfunction in vivo, determined by catheterization. Infarct size 24 h post-MI, shown by 2,3,5-triphenyltetrazolium chloride (TTC) staining, was similar at 24 h. Treatment with exogenous IL-6 did not alter MI size in WT. Infarction resulted in marked phosphorylation of STAT3, without differences between genotypes. Leukemia inhibitory factor (LIF) protein was increased 48 h post-MI in IL-6-/-, and angiotensin II and AT1 receptor (AT1R) protein were strongly increased in IL-6-/- baseline and post-MI, suggesting compensatory up-regulation. Lack of IL-6 does not affect long-term MI size or LV function, remodeling, and survival. In mice lacking IL-6, other members of the IL-6 family such as LIF and other factors signaling via JAK/STAT such as angiotensin may act in a compensatory manner to activate the JAK/STAT pathway, thereby maintaining STAT3 phosphorylation, which is crucial for the cellular effects of IL-6 cytokines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12958147     DOI: 10.1096/fj.03-0331fje

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  32 in total

1.  Correlation between genetic polymorphisms within the MAPK1/HIF-1/HO-1 signaling pathway and risk or prognosis of perimenopausal coronary artery disease.

Authors:  Nan Guo; Nan Zhang; Liqiu Yan; Xufen Cao; Jiawang Wang; Yunfei Wang
Journal:  Clin Cardiol       Date:  2017-04-26       Impact factor: 2.882

Review 2.  Obesity-Induced Changes in Adipose Tissue Microenvironment and Their Impact on Cardiovascular Disease.

Authors:  José J Fuster; Noriyuki Ouchi; Noyan Gokce; Kenneth Walsh
Journal:  Circ Res       Date:  2016-05-27       Impact factor: 17.367

Review 3.  The immune system and the remodeling infarcted heart: cell biological insights and therapeutic opportunities.

Authors:  Nikolaos G Frangogiannis
Journal:  J Cardiovasc Pharmacol       Date:  2014-03       Impact factor: 3.105

4.  The lack of cardiotrophin-1 alters expression of interleukin-6 and leukemia inhibitory factor mRNA but does not impair cardiac injury response.

Authors:  Kurt Gritman; Donna M Van Winkle; Christina U Lorentz; Diane Pennica; Beth A Habecker
Journal:  Cytokine       Date:  2006-12-05       Impact factor: 3.861

Review 5.  The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis.

Authors:  Sumanth D Prabhu; Nikolaos G Frangogiannis
Journal:  Circ Res       Date:  2016-06-24       Impact factor: 17.367

Review 6.  The immune system and cardiac repair.

Authors:  Nikolaos G Frangogiannis
Journal:  Pharmacol Res       Date:  2008-06-24       Impact factor: 7.658

7.  Deletion of Interleukin-6 Attenuates Pressure Overload-Induced Left Ventricular Hypertrophy and Dysfunction.

Authors:  Lin Zhao; Guangming Cheng; Runming Jin; Muhammad R Afzal; Anweshan Samanta; Yu-Ting Xuan; Magdy Girgis; Harold K Elias; Yanqing Zhu; Arash Davani; Yanjuan Yang; Xing Chen; Sheng Ye; Ou-Li Wang; Lei Chen; Jeryl Hauptman; Robert J Vincent; Buddhadeb Dawn
Journal:  Circ Res       Date:  2016-04-28       Impact factor: 17.367

8.  IL-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX-2.

Authors:  Buddhadeb Dawn; Yu-Ting Xuan; Yiru Guo; Arash Rezazadeh; Adam B Stein; Greg Hunt; Wen-Jian Wu; Wei Tan; Roberto Bolli
Journal:  Cardiovasc Res       Date:  2004-10-01       Impact factor: 10.787

Review 9.  Role of gp130-mediated signalling pathways in the heart and its impact on potential therapeutic aspects.

Authors:  P Fischer; D Hilfiker-Kleiner
Journal:  Br J Pharmacol       Date:  2008-02-04       Impact factor: 8.739

Review 10.  The inflammatory response in myocardial injury, repair, and remodelling.

Authors:  Nikolaos G Frangogiannis
Journal:  Nat Rev Cardiol       Date:  2014-03-25       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.